List of Uloric drug patents

Uloric is owned by Takeda Pharms Usa.

Uloric contains Febuxostat.

Uloric has a total of 3 drug patents out of which 0 drug patents have expired.

Uloric was authorised for market use on 13 February, 2009.

Uloric is available in tablet;oral dosage forms.

Uloric can be used as use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline.

The generics of Uloric are possible to be released after 08 September, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7361676 TAKEDA PHARMS USA Solid preparation containing single crystal form
Mar, 2024

(1 year, 1 month from now)

US8372872 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

US9107912 TAKEDA PHARMS USA Methods for concomitant treatment of theophylline and febuxostat
Sep, 2031

(8 years from now)

Drugs and Companies using FEBUXOSTAT ingredient

Market Authorisation Date: 13 February, 2009

Treatment: Use of febuxostat for the management of hyperuricemia in patients suffering from gout and, when used with theophylline without the need for dose adjustment of theophylline

Dosage: TABLET;ORAL

How can I launch a generic of ULORIC before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in